Beijing, China

Lifeng Ning

This inventor holds 1 USPTO granted patent. Top assignee: National Research Institute for Family Planning. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lifeng Ning. Retrieved from https://idiyas.com/inventor/lifeng-ning

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lifeng Ning and Cyclodextrin-Based Ethinylestradiol Innovation.

Introduction

Lifeng Ning is an inventor based in Beijing, China, and is associated with the National Research Institute for Family Planning. His patent work includes a formulation designed to improve the water solubility of ethinylestradiol.

Latest Patents

Ning is named on one patent, 1 patent: “Preparation for Ethinylestradiol-Cyclodextrin Complex and Use Thereof.” The invention uses cyclodextrin’s hydrophobic inner cavity and hydrophilic outer surface to form a complex with ethinylestradiol. The approach is intended to increase the drug’s solubility and bioavailability, potentially supporting alternative administration methods and homogeneous injection.

Career Highlights

Ning’s listed patent highlights research into pharmaceutical formulation and the delivery of a water-insoluble drug. The work focuses on using a cyclodextrin complex to address ethinylestradiol’s limited water solubility.

Collaborations

Juan Xu and Bin He are identified as Ning’s coworkers.

Conclusion

Lifeng Ning’s patent centers on a cyclodextrin-based formulation intended to improve ethinylestradiol’s solubility and broaden its potential administration options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…